Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available

The goal of this study is to derive data that large healthcare
organizations can combine data on risks of adverse events and cost
data to conduct cost-effectiveness / cost-benefit analyses for
pre-emptive pharmacogenomics testing